Linfoma difuso de grandes células B: marcadores biológicos de prognóstico e tratamento com anticorpo anti-cd20
Year: 2014
Type: article
Abstract: Despite great progress has been made in diffuse large B-cell lymphoma treatment, especially with the combination of the anti-CD20 antibody (rituximab) with the standard chemotherapy, this diseases clinical and biological heterogeneity is responsible for unpredictable responses to treatment and difficult prognostic assessment. The biological prognostication of these patients has been a target of incessant investigation, and several markers emerged as survival predictors in rituximabs era. However, the methods and expression cut-offs used varied between studies, creating inconsistencies in the obtained results. The identification of reliable and easily assessed prognostic biomarkers is extremely important, because it will allow creation of new target therapies and individualization of treatment regimens.
Authors: M. M. Queiroga Gomes, Fernando Prı́ncipe
Institution: Universidade do Porto
Language: Spanish
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W2515841651